Veru Inc Stock Research

Market Summary

USD1.04+0.06

Market Closed

6.15%

VERU Stock Price

VERU RSI Chart

VERU Valuation

Market Cap

80.6M

Price/Earnings (Trailing)

-0.58

Price/Sales (Trailing)

3.79

EV/EBITDA

-0.6

Price/Free Cashflow

-0.84

VERU Price/Sales (Trailing)

VERU Profitability

EBT Margin

-411.82%

Return on Equity

-232.67%

Return on Assets

-110.07%

Free Cashflow Yield

-118.71%

VERU Fundamentals

VERU Revenue

Revenue (TTM)

21.3M

Revenue Y/Y

-49.45%

Revenue Q/Q

162.62%

VERU Earnings

Earnings (TTM)

-138.9M

Earnings Y/Y

-173.62%

Earnings Q/Q

-5.29%

Price Action

52 Week Range

0.9324.55

(Low)(High)

Last 7 days

-5.2%

Last 30 days

-22.5%

Last 90 days

-59.7%

Trailing 12 Months

-92.0%

VERU Financial Health

Current Ratio

1.82

VERU Investor Care

Shares Dilution (1Y)

3.14%

Diluted EPS (TTM)

-1.74

Peers (Alternatives to Veru)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
PG	357.9B	81.0B	-7.97%	0.19%	25.07	4.46	1.70%	-1.88%
EL	67.4B	15.9B	-25.42%	-26.97%	44.6	4.25	-12.42%	-53.65%
CL	63.2B	18.3B	-7.36%	-3.00%	35.42	3.52	4.93%	-21.82%
CHD	22.9B	311.6M	-4.40%	5.64%	55.42	73.4	-94.06%	-49.12%
CLX	19.9B	7.2B	-5.43%	14.62%	269.56	2.78	0.89%	-83.84%
MID-CAP
COTY	9.8B	5.4B	-6.94%	56.11%	50.82	1.83	3.31%	-45.41%
ELF	5.6B	496.6M	16.13%	304.79%	119.4	11.26	30.80%	132.00%
IPAR	4.2B	1.1B	-16.67%	76.08%	30.21	3.68	23.19%	46.99%
SMALL-CAP
NUS	2.0B	2.1B	-15.65%	-28.13%	19.48	0.92	-19.87%	-44.11%
HLF	1.2B	5.1B	-16.13%	-45.17%	4.85	0.24	-9.16%	-36.58%
USNA	1.2B	974.1M	-8.89%	-14.19%	18.11	1.21	-15.40%	-39.77%
NATR	214.1M	420.1M	6.64%	-6.10%	389.21	0.51	-7.10%	-98.18%
VERU	80.6M	21.3M	-22.55%	-91.99%	-0.58	3.79	-64.80%	-404.09%
LFVN	60.3M	210.1M	41.59%	12.93%	-71.59	0.29	-0.04%	-108.92%
GHSI	7.7M	11.9M	9.30%	3462.68%	-0.84	0.65	26.28%	66.80%

Financials for Veru

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	-23.2%	21,284,587	27,727,014	39,354,352	52,412,181	60,465,578
Gross Profit	-36.4%	12,368,158	19,451,361	30,591,388	42,395,161	49,199,650
Operating Expenses	15.4%	153,871,394	133,300,795	113,814,948	82,817,411	70,669,989
S&GA Expenses	10.1%	59,426,860	53,991,504	43,168,845	30,806,142	25,603,886
R&D Expenses	9.2%	86,632,820	79,309,291	70,646,103	52,011,269	45,066,103
EBITDA	-39.1%	-110,101,383	-79,170,825	-42,464,879	-25,870,403	-
EBITDA Margin	-97.4%	-3.97	-2.01	-0.81	-0.43	-
Earnings Before Taxes	-21.6%	-138,838,914	-114,184,729	-83,539,623	-47,179,151	-30,687,107
EBT Margin	-94.0%	-4.12	-2.12	-0.90	-0.51	-
Interest Expenses	-12.6%	3,568,337	4,083,346	4,368,798	4,714,272	4,816,704
Net Income	-21.5%	-138,853,269	-114,238,193	-83,776,020	-47,047,892	-27,545,182
Net Income Margin	-93.5%	-4.12	-2.13	-0.90	-0.46	-
Free Cahsflow	-53.6%	-74,097,648	-48,238,056	-28,239,452	-27,097,193	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-32.3%	70.00	104	136	161	173
Current Assets	-40.7%	43.00	73.00	105	128	140
Inventory	-12.2%	8.00	9.00	9.00	8.00	6.00
Net PPE	6.6%	2.00	1.00	1.00	1.00	1.00
Goodwill	0%	7.00	7.00	7.00	7.00	7.00
Liabilities	-2.1%	54.00	55.00	55.00	44.00	37.00
Current Liabilities	-2.0%	39.00	40.00	41.00	28.00	21.00
Shareholder's Equity	-66.0%	17.00	49.00	81.00	117	136
Retained Earnings	-19.2%	-241	-202	-165	-124	-102
Additional Paid-In Capital	2.5%	265	259	254	249	246
Shares Outstanding	2.4%	83.00	81.00	81.00	80.00	80.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-29.4%	-94.99	-73.38	-47.51	-27.43	-26.25
Share Based Compensation	12.1%	16.00	14.00	11.00	8.00	7.00
Cashflow From Investing	2.4%	2.00	2.00	4.00	4.00	2.00
Cashflow From Financing	91.9%	5.00	2.00	1.00	1.00	-0.06

Risks for VERU

What is the probability of a big loss on VERU?

100%

Probability that Veru stock will be more than 20% underwater in next one year

88.8%

Probability that Veru stock will be more than 30% underwater in next one year.

86.5%

Probability that Veru stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VERU drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Veru was unfortunately bought at previous high price.

Drawdowns

Returns for VERU

Cumulative Returns on VERU

-20.3%

10-Year Cumulative Returns

-4.4%

7-Year Cumulative Returns

-13.9%

5-Year Cumulative Returns

-35.5%

3-Year Cumulative Returns

What are the long-term rolling returns for VERU?

FIve years rolling returns for Veru.

Annualized Returns

Which funds bought or sold VERU recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-25	Empower Advisory Group, LLC	new	-	12,596	12,596	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-36.05	-213,000	35,000	-%
2023-05-18	JPMORGAN CHASE & CO	added	163	-216,000	296,000	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	529	45,956	166,044	-%
2023-05-16	MERCER GLOBAL ADVISORS INC /ADV	reduced	-17.85	-80,000	18,000	-%
2023-05-16	PERCEPTIVE ADVISORS LLC	reduced	-45.3	-36,504,400	4,985,930	0.15%
2023-05-16	JANE STREET GROUP, LLC	reduced	-20.75	-320,709	67,609	-%
2023-05-16	SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC	sold off	-100	-54,384	-	-%
2023-05-16	Rockefeller Capital Management L.P.	sold off	-100	-12,000	-	-%
2023-05-15	BAKER BROS. ADVISORS LP	unchanged	-	-6,631,460	1,867,110	0.01%

Latest Funds Activity

Are funds buying VERU calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own VERU

No. of Funds

Veru News

Schedule 13G FIlings of Veru

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 19, 2023	frost phillip md et al	6.1%	5,000,253	SC 13G
Feb 14, 2023	tang capital partners lp	0.0%	0	SC 13G/A
Feb 14, 2023	perceptive advisors llc	9.7%	7,858,011	SC 13G
Nov 14, 2022	ra capital management, l.p.	0%	0	SC 13G/A
Jun 06, 2022	tang capital partners lp	5.2%	4,130,339	SC 13G
Apr 21, 2022	ra capital management, l.p.	9.87%	7,900,000	SC 13G
Feb 10, 2022	vanguard group inc	3.79%	3,029,395	SC 13G/A
Feb 07, 2022	blackrock inc.	5.3%	4,211,371	SC 13G
Mar 10, 2021	blackrock inc.	4.8%	3,740,056	SC 13G/A
Feb 10, 2021	vanguard group inc	5.24%	3,671,810	SC 13G

VERU Fair Value

Show Fair-Value

Recent SEC filings of Veru

View All Filings

Date Filed	Form Type	Document
May 24, 2023	EFFECT	EFFECT
May 15, 2023	PRE 14A	PRE 14A
May 12, 2023	424B5	Prospectus Filed
May 12, 2023	8-K	Current Report
May 12, 2023	S-3	S-3
May 11, 2023	4	Insider Trading
May 11, 2023	10-Q	Quarterly Report
May 11, 2023	4	Insider Trading
May 11, 2023	4	Insider Trading
May 11, 2023	4	Insider Trading

Latest Insider Trading transactions for VERU

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-08-15	Eisenberger Mario	acquired	156,950	1.5695	100,000	-
2022-08-15	Eisenberger Mario	sold	-2,003,550	20.0355	-100,000	-
2021-08-17	Lu Lucy	bought	32,542	6.7796	4,800	-
2021-06-16	FISCH HARRY	sold	-835,300	8.353	-100,000	-
2021-03-10	Hyun Grace	bought	49,315	14.09	3,500	-
2021-02-12	STEINER MITCHELL SHUSTER	sold	-417,688	20.8844	-20,000	president and ceo
2020-12-16	STEINER MITCHELL SHUSTER	sold	-2,421,620	9.6865	-250,000	president and ceo
2020-12-16	BARNETTE K GARY	sold	-1,064,510	10.6451	-100,000	chief scientific officer
2020-08-26	FISCH HARRY	bought	13,799	2.7599	5,000	-
2020-08-24	Greco Michele	bought	13,233	2.6466	5,000	cao and cfo

About Veru

Mitchell S. Steiner

www.femalehealth.com

250

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

VERU Income Statement

2023-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Net revenues	$ 6,585,967	$ 13,028,394	$ 9,093,761	$ 27,163,526
Cost of sales	2,493,892	1,853,116	4,299,631	4,146,166
Gross profit	4,092,075	11,175,278	4,794,130	23,017,360
Operating expenses:
Research and development	22,864,633	15,541,104	41,608,982	25,622,265
Selling, general and administrative	12,834,494	7,401,138	30,380,359	14,126,344
Provision for (recovery of) credit losses	3,911,714	(2,000)	3,911,714	(4,000)
Impairment of intangible assets	3,900,000		3,900,000
Total operating expenses	43,510,841	22,940,242	79,801,055	39,744,609
Operating loss	(39,418,766)	(11,764,964)	(75,006,925)	(16,727,249)
Non-operating income (expenses):
Interest expense	(697,693)	(1,212,702)	(1,570,923)	(2,371,384)
Change in fair value of derivative liabilities	1,200,000	(1,229,000)	530,000	(1,438,000)
Other income, net	56,994	1,386	277,926	66,002
Total non-operating income (expenses)	559,301	(2,440,316)	(762,997)	(3,743,382)
Loss before income taxes	(38,859,465)	(14,205,280)	(75,769,922)	(20,470,631)
Income tax (benefit) expense	(66,559)	(27,450)	(134,837)	87,205
Net loss	$ (38,792,906)	$ (14,177,830)	$ (75,635,085)	$ (20,557,836)
Net loss per basic common shares outstanding	$ (0.48)	$ (0.18)	$ (0.94)	$ (0.26)
Basic weighted average common shares outstanding	80,834,453	80,052,504	80,695,046	80,037,675
Net loss per diluted common share outstanding	$ (0.48)	$ (0.18)	$ (0.94)	$ (0.26)
Diluted weighted average common shares outstanding	80,834,453	80,052,504	80,695,046	80,037,675

VERU Balance Sheet

2023-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Sep. 30, 2022
Current assets:
Cash and cash equivalents	$ 23,498,371	$ 80,190,675
Accounts receivable, net	4,205,967	3,550,895
Inventories, net	7,665,194	8,618,944
Prepaid research and development costs	5,787,224	10,444,587
Prepaid expenses and other current assets	2,131,521	1,964,373
Total current assets	43,288,277	104,769,474
Property and equipment, net	1,519,789	1,185,766
Operating lease right-of-use assets	4,675,739	4,786,915
Deferred income taxes	13,070,469	12,965,985
Intangible assets, net	41,667	3,977,381
Goodwill	6,878,932	6,878,932
Other assets	778,697	1,561,564
Total assets	70,253,570	136,126,017
Current liabilities:
Accounts payable	17,237,474	22,003,394
Accrued research and development costs	13,786,241	9,071,503
Accrued compensation	2,986,624	5,986,557
Accrued expenses and other current liabilities	2,811,453	2,249,995
Residual royalty agreement liability, short-term portion	1,354,823	1,169,095
Operating lease liability, short-term portion	1,083,183	957,085
Total current liabilities	39,259,798	41,437,629
Residual royalty agreement liability, long-term portion	10,257,325	9,656,441
Operating lease liability, long-term portion	3,987,612	4,093,667
Deferred income taxes		81,067
Other liabilities	32,933	18,577
Total liabilities	53,537,668	55,287,381
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, no shares issued and outstanding at March 31, 2023 and September 30, 2022
Common stock, par value $0.01 per share; 154,000,000 shares authorized, 84,760,736 and 82,692,598 shares issued and 82,577,032 and 80,508,894 shares outstanding at March 31, 2023 and September 30, 2022, respectively	847,607	826,926
Additional paid-in-capital	265,465,702	253,974,032
Accumulated other comprehensive loss	(581,519)	(581,519)
Accumulated deficit	(241,209,283)	(165,574,198)
Treasury stock, 2,183,704 shares, at cost	(7,806,605)	(7,806,605)
Total stockholders' equity	16,715,902	80,838,636
Total liabilities and stockholders' equity	$ 70,253,570	$ 136,126,017